Total Payments
$27,853
2024 Payments
$1,189
Companies
34
Transactions
358
Medicare Patients
4,127
Medicare Billing
$1.1M
Payment Breakdown by Category
Other$11,250 (40.4%)
Food & Beverage$10,879 (39.1%)
Travel$4,524 (16.2%)
Consulting$1,200 (4.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Grant | $11,250 | 1 | 40.4% |
| Food and Beverage | $10,879 | 325 | 39.1% |
| Travel and Lodging | $4,524 | 31 | 16.2% |
| Consulting Fee | $1,200 | 1 | 4.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic USA, Inc. | $11,250 | 1 | $0 (2019) |
| Medtronic, Inc. | $4,836 | 76 | $0 (2023) |
| Boston Scientific Corporation | $4,434 | 90 | $0 (2024) |
| Biohaven Pharmaceutical Holding Company Ltd. | $1,968 | 10 | $0 (2022) |
| Nevro Corp. | $1,038 | 14 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $726.53 | 42 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $593.72 | 5 | $0 (2020) |
| ABBVIE INC. | $585.55 | 24 | $0 (2024) |
| Collegium Pharmaceutical, Inc. | $548.61 | 31 | $0 (2024) |
| Curonix LLC | $331.24 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,189 | 51 | Boston Scientific Corporation ($424.21) |
| 2023 | $3,281 | 114 | Medtronic, Inc. ($1,160) |
| 2022 | $5,053 | 84 | Biohaven Pharmaceutical Holding Company Ltd. ($1,968) |
| 2021 | $4,031 | 77 | Medtronic, Inc. ($1,811) |
| 2020 | $1,237 | 16 | Boston Scientific Corporation ($682.61) |
| 2019 | $12,591 | 11 | Medtronic USA, Inc. ($11,250) |
| 2018 | $471.52 | 5 | Merck Sharp & Dohme Corporation ($348.00) |
All Payment Transactions
358 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $6.29 | General |
| Category: Opioid Analgesic | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: Gastroenterology | ||||||
| 11/22/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $22.86 | General |
| Category: Opioid Analgesic | ||||||
| 11/21/2024 | Valinor Pharma, LLC | MOVANTIK (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/20/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: PAIN | ||||||
| 11/01/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Analgesic | ||||||
| 10/31/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $6.77 | General |
| Category: Opioid Analgesic | ||||||
| 10/22/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $14.09 | General |
| Category: NEUROSCIENCE | ||||||
| 10/16/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: PAIN | ||||||
| 10/05/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $21.10 | General |
| Category: Opioid Analgesic | ||||||
| 09/23/2024 | Octapharma USA, Inc. | FIBRYGA (Biological) | Food and Beverage | In-kind items and services | $36.83 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 09/23/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Analgesic | ||||||
| 09/09/2024 | SI-BONE, INC. | — | Food and Beverage | Cash or cash equivalent | $24.35 | General |
| 09/04/2024 | Vision Quest Industries Inc. | PRO estim NMES Stimulator (Device), Avid CT2 NMES/IFC STIMULATOR | Food and Beverage | In-kind items and services | $67.80 | General |
| Category: NMES | ||||||
| 08/29/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $22.28 | General |
| Category: Opioid Analgesic | ||||||
| 08/27/2024 | Boston Scientific Corporation | WaveWriter Alpha Prime 16 (Device) | Food and Beverage | In-kind items and services | $50.45 | General |
| Category: WaveWriter Alpha_NMD | ||||||
| 08/21/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: Gastroenterology | ||||||
| 08/14/2024 | Valinor Pharma, LLC | MOVANTIK (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/06/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $104.34 | General |
| Category: General - Pain Management_NMD | ||||||
| 08/06/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $6.75 | General |
| Category: Opioid Analgesic | ||||||
| 08/01/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $45.97 | General |
| Category: General - Pain Management_NMD | ||||||
| 07/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: Gastroenterology | ||||||
| 07/24/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $22.64 | General |
| Category: Gastroenterology | ||||||
| 07/23/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: PAIN | ||||||
| 07/18/2024 | Boston Scientific Corporation | WaveWriter Alpha Prime 16 (Device) | Food and Beverage | In-kind items and services | $12.22 | General |
| Category: WaveWriter Alpha_NMD | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 1,704 | 6,329 | $1.5M | $536,171 |
| 2022 | 23 | 1,317 | 3,045 | $1.0M | $322,538 |
| 2021 | 21 | 852 | 2,272 | $845,960 | $225,857 |
| 2020 | 12 | 254 | 514 | $207,987 | $48,197 |
Total Patients
4,127
Total Services
12,160
Medicare Billing
$1.1M
Procedure Codes
97
All Medicare Procedures & Services
97 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 336 | 2,642 | $715,982 | $273,979 | 38.3% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Office | 2023 | 73 | 134 | $133,712 | $51,035 | 38.2% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Office | 2023 | 85 | 134 | $107,858 | $33,751 | 31.3% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Office | 2023 | 73 | 135 | $74,934 | $28,509 | 38.0% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Office | 2023 | 50 | 75 | $57,000 | $16,938 | 29.7% |
| 64479 | Injection of anesthetic and/or steroid drug into upper or middle spine nerve root using imaging guidance, single level | Office | 2023 | 30 | 46 | $42,486 | $13,243 | 31.2% |
| 64633 | Destruction of upper or middle spinal facet joint nerves using imaging guidance, single facet joint | Office | 2023 | 16 | 30 | $29,010 | $11,335 | 39.1% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 68 | 200 | $26,600 | $9,873 | 37.1% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Office | 2023 | 86 | 205 | $22,755 | $8,729 | 38.4% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Office | 2023 | 50 | 75 | $29,204 | $8,687 | 29.7% |
| 64625 | Destruction of nerves supplying joint between spine and pelvis using imaging guidance | Office | 2023 | 11 | 18 | $21,945 | $7,773 | 35.4% |
| 64634 | Destruction of upper or middle spinal facet joint nerves using imaging guidance, each additional facet joint | Office | 2023 | 16 | 32 | $18,400 | $7,156 | 38.9% |
| 64484 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | Office | 2023 | 52 | 74 | $19,680 | $6,959 | 35.4% |
| 64450 | Injection of anesthetic agent and/or steroid into other nerve or branch | Office | 2023 | 27 | 159 | $31,652 | $6,099 | 19.3% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 237 | 479 | $14,370 | $5,904 | 41.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 32 | 32 | $14,912 | $5,732 | 38.4% |
| 27096 | Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | Office | 2023 | 20 | 24 | $15,532 | $4,819 | 31.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $11,649 | $4,542 | 39.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 44 | 59 | $11,328 | $4,493 | 39.7% |
| 64490 | Injection of upper or middle spine facet joint using imaging guidance, single level | Office | 2023 | 11 | 17 | $14,076 | $3,990 | 28.3% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2023 | 146 | 768 | $7,608 | $3,989 | 52.4% |
| 64451 | Injection of anesthetic agent and/or steroid into spine and pelvis nerve using imaging guidance | Office | 2023 | 11 | 12 | $11,638 | $3,449 | 29.6% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Office | 2023 | 12 | 15 | $8,550 | $3,352 | 39.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 27 | $10,287 | $3,029 | 29.4% |
| 64480 | Injection of anesthetic and/or steroid drug into upper or middle spine nerve root using imaging guidance, each additional level | Office | 2023 | 17 | 21 | $6,808 | $2,542 | 37.3% |
About Dr. Murad Arif, MD
Dr. Murad Arif, MD is a Addiction Medicine healthcare provider based in Murrieta, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2018. The National Provider Identifier (NPI) number assigned to this provider is 1164925038.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Murad Arif, MD has received a total of $27,853 in payments from pharmaceutical and medical device companies, with $1,189 received in 2024. These payments were reported across 358 transactions from 34 companies. The most common payment nature is "Grant" ($11,250).
As a Medicare-enrolled provider, Arif has provided services to 4,127 Medicare beneficiaries, totaling 12,160 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 97 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction Medicine
- Other Specialties Interventional Pain Medicine, Anesthesiology
- Location Murrieta, CA
- Active Since 03/16/2018
- Last Updated 01/26/2025
- Taxonomy Code 2083A0300X
- Entity Type Individual
- NPI Number 1164925038
Products in Payments
- SYNCHROMED (Device) $11,250
- NURTEC ODT (Drug) $2,170
- INTELLIS ADAPTIVESTIM (Device) $1,940
- SPECTRA WAVEWRITER (Device) $1,841
- INTELLIS (Device) $1,647
- VANTA ADAPTIVESTIM (Device) $1,038
- Senza Spinal Cord Stimulation System (Device) $741.70
- RELISTOR (Drug) $726.53
- WaveWriter Alpha Prime 16 (Device) $630.36
- BRIDION (Drug) $593.72
- General - Pain Management (Device) $467.14
- WAVEWRITER ALPHA (Device) $422.73
- Belbuca (Drug) $334.97
- UBRELVY (Drug) $334.88
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A (Device) $331.24
- Omnia (Device) $296.21
- QULIPTA (Drug) $250.67
- XTAMPZA (Drug) $213.64
- GENERAL - PAIN MANAGEMENT (Device) $180.92
- QUVIVIQ (Drug) $172.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.